Business Wire

BiologIC Technologies Helps Implement High-throughput Heat Inactivation of Patient Samples at Cambridge Lighthouse Laboratory

29.4.2021 09:00:00 EEST | Business Wire | Press release

Share

BiologIC Technologies, a pioneer in Industry 4.0 technologies for the bio-revolution, has collaborated with AstraZeneca and Electrolux Professional to implement a high-throughput solution for heat inactivation of patient samples at the Cambridge Lighthouse Laboratory. This solution renders the virus non-infectious, enhancing the safety, sustainability and scalability of the testing process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005091/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BiologIC Technologies helps implement high-throughput heat inactivation of patient samples at Cambridge UK COVID-19 Test Centre. (Photo: Business Wire)

The Cambridge Lighthouse Laboratory, established by AstraZeneca, the University of Cambridge and GlaxoSmithKline, and subsequently partnering with Charles River Laboratories, was part of NHS Test and Trace’s network of Lighthouse laboratories which provides population-wide diagnostic testing.

BiologIC, AstraZeneca and Electrolux Professional combined bioscience and thermal expertise to rapidly implement an innovative, production-ready heat inactivation solution in this safety-critical process. Rigorous validation demonstrated inactivation of the COVID-19 virus whilst maintaining the accuracy of diagnostic testing. The parties have now successfully implemented this solution, using Skyline Ovens from Electrolux Professional.

Richard Vellacott, CEO of BiologIC Technologies:

"Combined with vaccines, diagnostic testing will be critical to re-mobilising our local, national and international communities, particularly as new strains of COVID-19 continue to evolve. We were pleased to identify, validate and support implementation of this solution to greatly enhance the safety, cost-effectiveness and scalability of COVID-19 diagnostic testing."

Steve Rees, VP Discovery Biology, R&D, AstraZeneca:

“Our collaborative innovative solution enables virus inactivation upon receipt at the laboratory allowing work on the open bench, which simplifies the workflow, reduces the risk of employee exposure to live virus, and facilitates future innovations around automation of the sample unpackaging process.”

Alberto Zanata, CEO of Electrolux Professional:

“With the advanced technology of the SkyLine combi oven, we support yet another milestone in fighting the pandemic that is affecting people and businesses around the world. We are very proud to play a role in safeguarding the process of handling the COVID-19 samples, to protect all people involved in testing.”

Ends

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information from BiologIC Technologies
Richard Vellacott, CEO
richard.vellacott@biologic-tech.com

Dr Colin Barker, CSO
colin.barker@biologic-tech.com
Phone: +44(0)1353 725 816
https://www.biologic-tech.com/solutions/virology

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release

Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e

Corpay Cross-Border Named the Official FX Partner of Ultimate Sevens5.8.2026 16:36:00 EEST | Press release

Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Ultimate Sevens, a new global rugby sevens championship backed by BIA Sports Group launching in August 2026. Under the agreement, Corpay becomes Ultimate Sevens exclusive and Official Foreign Exchange (FX) Partner, along with being an Ultimate Sevens Playmaker. As the Championships’ exclusive foreign exchange partner, Corpay Cross-Border will provide Ultimate Sevens with comprehensive FX risk management solutions to help manage foreign exchange exposure from its day-to-day business activities. Corpay Cross-Border’s award-winning platform will also enable Ultimate Sevens to manage global payments through a single point of access. “Corpay Cross-Border is thrilled to be named the exclusive and official FX partner of Ultimate Sevens,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “The team at Ultimate Sev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye